【胰臟癌】《Actuate: ACTU》利用給藥前血漿生物標記與ML，預測「胰腺癌」總存活期

 【胰臟癌】《Actuate: ACTU》利用給藥前血漿生物標記與ML，預測「胰腺癌」總存活期

 文章出處  

Globe Newswire 

 

 原文標題  

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO 

 

 Twitter  

https://x.com/aimedadviser/status/1936948419190509847 

 

 文章序號  

8325 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2025 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.